William Blair Issues Positive Forecast for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair lifted their Q2 2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will earn ($0.09) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.29) EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the business posted ($0.40) EPS.

Other equities research analysts have also issued reports about the company. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Stock Up 0.9%

Shares of Zevra Therapeutics stock traded up $0.08 on Monday, hitting $8.65. The company had a trading volume of 375,522 shares, compared to its average volume of 643,411. The stock has a market capitalization of $472.98 million, a price-to-earnings ratio of -4.39 and a beta of 1.87. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The stock has a 50 day moving average of $7.59 and a 200-day moving average of $8.09. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares during the last quarter. IFG Advisors LLC increased its position in Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock worth $242,000 after buying an additional 2,650 shares during the last quarter. Invesco Ltd. increased its position in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after buying an additional 3,007 shares during the last quarter. Corebridge Financial Inc. increased its position in Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock worth $219,000 after buying an additional 3,801 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock worth $1,148,000 after buying an additional 3,827 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

Insider Buying and Selling

In related news, Director John B. Bode acquired 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company's stock, valued at approximately $318,400. This represents a 33.33% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is currently owned by corporate insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.